Neurocrine Biosciences, Inc. (NBIX)
143.18
+2.47
(+1.76%)
USD |
NASDAQ |
Oct 02, 16:00
144.60
+1.42
(+0.99%)
After-Hours: 20:00
Neurocrine Biosciences Enterprise Value : 14.56B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 14.56B |
| October 01, 2026 | 14.31B |
| September 30, 2026 | 14.42B |
| September 29, 2026 | 14.07B |
| September 28, 2026 | 14.28B |
| September 25, 2026 | 14.07B |
| September 24, 2026 | 14.13B |
| September 23, 2026 | 14.18B |
| September 22, 2026 | 14.46B |
| September 21, 2026 | 14.64B |
| September 18, 2026 | 14.87B |
| September 17, 2026 | 15.44B |
| September 16, 2026 | 15.20B |
| September 15, 2026 | 15.25B |
| September 14, 2026 | 15.99B |
| September 11, 2026 | 15.88B |
| September 10, 2026 | 15.92B |
| September 09, 2026 | 15.77B |
| September 08, 2026 | 15.77B |
| September 04, 2026 | 15.83B |
| September 03, 2026 | 16.10B |
| September 02, 2026 | 16.04B |
| September 01, 2026 | 15.94B |
| August 31, 2026 | 15.66B |
| August 28, 2026 | 15.66B |
| Date | Value |
|---|---|
| August 27, 2026 | 15.85B |
| August 26, 2026 | 15.92B |
| August 25, 2026 | 15.59B |
| August 24, 2026 | 15.56B |
| August 21, 2026 | 15.51B |
| August 20, 2026 | 15.55B |
| August 19, 2026 | 15.81B |
| August 18, 2026 | 15.68B |
| August 17, 2026 | 15.71B |
| August 14, 2026 | 15.53B |
| August 13, 2026 | 15.34B |
| August 12, 2026 | 15.91B |
| August 11, 2026 | 16.47B |
| August 10, 2026 | 16.77B |
| August 07, 2026 | 16.61B |
| August 06, 2026 | 16.25B |
| August 05, 2026 | 16.42B |
| August 04, 2026 | 16.88B |
| August 03, 2026 | 16.90B |
| July 31, 2026 | 16.96B |
| July 30, 2026 | 18.86B |
| July 29, 2026 | 18.38B |
| July 28, 2026 | 18.59B |
| July 27, 2026 | 17.94B |
| July 24, 2026 | 17.87B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Amarin Corp. Plc | -50.22M |
| Liquidia Corp. | 2.451B |
| BioCryst Pharmaceuticals, Inc. | 2.569B |
| Halozyme Therapeutics, Inc. | 14.44B |
| Iovance Biotherapeutics, Inc. | 6.187B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 144.40M |
| Revenue (Quarterly) | 959.00M |
| Total Expenses (Quarterly) | 814.60M |
| EPS Diluted (Quarterly) | 1.386 |
| Gross Profit Margin (Quarterly) | 95.87% |
| Profit Margin (Quarterly) | 15.06% |
| Earnings Yield | 4.77% |
| Operating Earnings Yield | 5.44% |
| Normalized Earnings Yield | 4.672 |